ReviewDrugs2014
Defining phenotypes in asthma: a step towards personalized medicine.
Review in Drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 83 citations in OpenAlex.
- Economic Evaluation of Mepolizumab as Add-on Therapy to Standard Care in Severe Eosinophilic Asthma: A Cost-Effectiveness Analysis in Colombia.Journal of asthma and allergy · 2025Article
- Article
- Single-cell analysis reveals alterations in cellular composition and cell-cell communication associated with airway inflammation and remodeling in asthma.Respiratory research · 2024Article
- Open-set recognition of breast cancer treatments.Artificial intelligence in medicine · 2023Article
- Physical activity phenotypes and mortality in older adults: a novel distributional data analysis of accelerometry in the NHANES.Aging clinical and experimental research · 2022Article
- Measurement of Exhaled Volatile Organic Compounds as a Biomarker for Personalised Medicine: Assessment of Short-Term Repeatability in Severe Asthma.Journal of personalized medicine · 2022Article
- Article
- Treatable Mechanisms in Asthma.Molecular diagnosis & therapy · 2021Article
- Investigation of molecular mechanisms of experimental compounds in murine models of chronic allergic airways disease using synchrotron Fourier-transform infrared microspectroscopy.Scientific reports · 2020Article
- Airway smooth muscle cells are insensitive to the anti-proliferative effects of corticosteroids: The novel role of insulin growth factor binding Protein-1 in asthma.Immunobiology · 2019Article
- Expansion of different subpopulations of CD26Scientific reports · 2019Article
- Paucigranulocytic asthma: Uncoupling of airway obstruction from inflammation.The Journal of allergy and clinical immunology · 2019Review
- Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort.PloS one · 2018Article
- Integrated Modules Analysis to Explore the Molecular Mechanisms of Phlegm-Stasis Cementation Syndrome with Ischemic Heart Disease.Frontiers in physiology · 2018Article
- Spectrum of T-lymphocyte activities regulating allergic lung inflammation.Immunological reviews · 2017Review
- Airway Microbiota in Severe Asthma and Relationship to Asthma Severity and Phenotypes.PloS one · 2016Article
- Mepolizumab: First Global Approval.Drugs · 2015Review
- Measuring the corticosteroid responsiveness endophenotype in asthmatic patients.The Journal of allergy and clinical immunology · 2015Article
- Biological monitoring of particulate matter accumulated in the lungs of urban asthmatic children in the Tel-Aviv area.International archives of occupational and environmental health · 2015Article
- Clinical phenotype network: the underlying mechanism for personalized diagnosis and treatment of traditional Chinese medicine.Frontiers of medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a common disease with a complex pathophysiology. It can present in various clinical forms and with different levels of severity. Unbiased cluster analytic methods have unravelled several phenotypes in cohorts representative of the whole spectrum of severity. Clusters of severe asthma include those on high-dose corticosteroid treatment, often with both inhaled and oral treatment, usually associated with severe airflow obstruction. Phenotypes with concordance between symptoms and sputum eosinophilia have been reported, including an eosinophilic inflammation-predominant group with few symptoms and late-onset disease who have a high prevalence of rhinosinusitis, aspirin sensitivity, and exacerbations. Sputum eosinophilia is also a biomarker that can predict therapeutic responses to antibody-based treatments to block the effects of the T-helper (Th)-2 cytokine, interleukin (IL)-5. Low Th2-expression has been predictive of poor therapeutic response to inhaled corticosteroid therapy. Current asthma schedules emphasise a step-up approach to treating asthma in relation to increasing severity, but, in more severe disease, phenotyping or endotyping of asthma will be necessary to determine new treatment strategies as severe asthma is recognized as being a particularly heterogeneous disease. Much less is known about 'non-eosinophilic' asthma. Phenotypic characterisation of corticosteroid insensitivity and chronic airflow obstruction of severe asthma is also needed. Phenotype-driven treatment of asthma will be further boosted by the advent of transcriptomic and proteomic technologies, with the application of systems biology or medicine approaches to defining phenotypes and biomarkers of disease and therapeutic response. This will pave the way towards personalized medicine and healthcare for asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.